Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1; 2 ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России, 355017, Россия, Ставрополь, ул. Мира, д. 310; 3 Независимый исследователь в области психофармакологии (Израиль, г. Азур).
Список исп. литературыСкрыть список 1. Беккер РА, Быков ЮВ. Об эффективности и безопасности применения тразодона в лечении нейропсихиатрических последствий постковидного синдрома (Обзор литературы и представление двух клинических случаев) // Психиатрия и психофармакотерапия. 2021. Т. 23. № 6. С. 28-43. 2. Беккер РА, Быков ЮВ. Тревожные и диссомнические депрессии: клиника, диагностика, терапия и эффективность препарата Рокона®(флувоксамин) // Психиатрия и психофармакотерапия. 2019. Т. 21. №. 3. С. 17-23. 3. Беккер РА, Быков ЮВ. Флувоксамин: антидепрессант широкого спектра с рядом особенностей и преимуществ (обзор литературы). // Психиатрия и психофармакотерапия. 2019. T. 21. №. 1. С. 11-26. 4. Морозов ПВ, Беккер РА, Быков ЮВ. О возможной роли некоторых психотропных препаратов в терапии COVID-19 (Краткий обзор) // Экспериментальная и клиническая фармакология. 2021. Т. 84. № 2. С. 104-112. 5. Петрова НН, Морозов ПВ, Маркин АВ, Беккер РА, Быков ЮВ. Пандемия COVID-19: актуальные вызовы времени, а также новейшие данные к вопросу рационального выбора психофармакотерапии у пациентов с SARS-COV-2 // Психиатрия и психофармакотерапия. 2020. Т. 22. № 6. С. 8-24. 6. Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Adv Exp Med Biol. 2017;964:153–161. 7. Alek Korab, 2021. Doctor Says These Existing Drugs Can Help Long COVID. Available at: https://www.msn.com/en-us/health/medical/doctor-says-these-existing-drugs-can-help-long-covid/ar-AAM.... Доступ проверен 10.07. 2022. 8. Amenta EM, Spallone A, Rodriguez-Barradas MC et al. Postacute COVID-19: An Overview and Approach to Classification. Open Forum Infect. Dis. 2020;7:ofaa509. 9. Asif M, Saleem M, Saadullah M et al. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. Inflammopharmacology. 2020;28(5):1153–1161. 10. Bektas A, Schurman SH, Franceschi C, Ferrucci L. A public health perspective of aging: Do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging? Immun. Ageing. 2020;17:23. 11. Bendau A, Petzold MB, Wyka S et al. [Anxiety in times of COVID-19 and other health crises]. [Article in German]. Nervenarzt. 2021;92(5):417-425. 12. Benedetti F, Poletti S, Hoogenboezem TA al. Inflammatory cytokines influence measures of white matter integrity in Bipolar Disorder. J. Affect. Disord. 2016;202:1–9. 13. Bhuiyan S, Tagashira H, Fukunaga K. Crucial interactions between selective serotonin uptake inhibitors and sigma-1 receptor in heart failure. J Pharmacol Sci. 2013;121(3):177-184. doi: 10.1254/jphs.12r13cp. 14. Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav. Immun. 2011;25:221–229. 15. Bogár F, Fülöp L, Penke B. Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands. Biomolecules. 2022;12(3):363. doi: 10.3390/biom12030363. 16. Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. JAMA Psychiatry. 2021;78(6):682–683. doi:10.1001/jamapsychiatry.2021.0500. 17. Brimson JM, Brimson S, Chomchoei C, Tencomnao T. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets. 2020;24(10):1009-1028. 18. Carod-Artal FJ. Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved. [Article in English, Spanish]. Rev Neurol. 2021;72(11):384-396. 19. CDC guideline on long COVID. Updated 2021. Available at: https:// www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-management.html. Доступ проверен 10.07.2022. 20. Chen Y, Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 2013;23(11):547-555. doi: 10.1016/j.tcb.2013.06.005. 21. Cobos EJ, Entrena JM, Nieto FR et al. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol. 2008;6(4):344–366. 22. Costa LA, Santos BM, Branco LS. Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19? Eur. J. Pharmacol. 2020; 889:173629. 23. Czarny P, Wigner P, Galecki P, Sliwinski T. The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018;80:309–321. 24. Dalwadi DA, Kim S, Schetz J et al. Brain-derived neurotrophic factor for high-throughput evaluation of selective Sigma-1 receptor ligands. J Pharmacol Toxicol Methods. 2022;113:107129. doi: 10.1016/j.vascn.2021.107129. 25. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry. 2010;67:446–457. 26. Ettman CK, Abdalla SM, Cohen GH et al. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9):e2019686. 27. Facente SN, Reiersen AM, Lenze EJ. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence. Drugs. 2021;81(18): 2081-2089. 28. FDA News, 2022. Available at: https://www.fdanews.com/articles/207841-icer-says-no-to-molnupiravir-yes-to-paxlovid-and-fluvoxamine... Доступ проверен 10.07.2022. 29. FLCCC Protocol I-RECOVER for Long COVID treatment. Available at: https://covid19criticalcare.com/covid-19-protocols/i-recover-long-covid-treatment/ Доступ проверен 08.06.2022. 30. Friesland M, Mingorance L, Chung J et al. Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J. Virol. 2013;87:6377. 31. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases. Ann Gen Psychiatry. 2010;9:18. doi: 10.1186/1744-859X-9-18. 32. Gennaro MM, Mariagrazia P, De Lorenzo R et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav. Immun. 2021;94:138–147. 33. Ghareghani M, Zibara K, Sadeghi H et al. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci. Rep. 2017;7:4923. 34. Gordon DE, Hiatt J, Bouhaddou M, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020 doi: 10.1126/science.abe9403. 35. Gordon DE, Jang GM, Bouhaddou M et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–468. 36. Gris G, Cobos EJ, Zamanillo D, Portillo-Salido E. Sigma-1 receptor and inflammatory pain. Inflamm Res. 2015;64(6):377-381. doi: 10.1007/s00011-015-0819-8. 37. Guo CM, Harari O, Chernecki С et al. Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials. Am J Trop Med Hyg. 2022;106(5):1315-1320. doi: 10.4269/ajtmh.21-1310. 38. Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Dispos. 2007;35(8):1325–1332. 39. Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci. 2015;127(1):6–9. 40. Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021;271(2):249-258. doi: 10.1007/s00406-020-01231-x. 41. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15-29. doi: 10.1016/j.pneurobio.2012.09.001. 42. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets. 2008;12(1):45–58. 43. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131:596–610. 44. Hong WC, Yano H, Hiranita T et al. The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. J Biol Chem. 2017;292(27):11250-11261. doi: 10.1074/jbc.M116.774075. 45. Huang C, Huang L, Wang Y et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220–232. 46. ICER Assessment, 2022. Available at: https://icer.org/assessment/covid-19-2022/ Доступ проверен 10.07.2022. 47. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167–173. 48. Jerčić L, Sandra Kostić S, Uljević MV et al. Sigma-1 Receptor Expression in DRG Neurons During a Carrageenan-Provoked Inflammation. Anat Rec (Hoboken). 2019;302(9):1620-1627. doi: 10.1002/ar.24061. 49. Jia J, Cheng J, Wang C, Zhen X. Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Front Cell Neurosci. 2018;12:314. doi: 10.3389/fncel.2018.00314. 50. Kim SW, Park IH, Kim M et al. Risk and protective factors of depression in the general population during the COVID-19 epidemic in Korea. BMC Psychiatry. 2021;21(1):445. 51. Koumpa FS, Forde CT, Manjaly JG. Sudden irreversible hearing loss post COVID-19. BMJ Case Rep. 2020;13:e238419. 52. Kourrich S, Tsung-Ping Su TP, Fujimoto M, Bonci A. The sigma-1 receptor: roles in neuronal plasticity and disease. Trends Neurosci. 2012;35(12):762-71. doi: 10.1016/j.tins.2012.09.007. 53. Lee TC, Vigod S, Bortolussi-Courval E et al. Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(4):e226269. doi: 10.1001/jamanetworkopen.2022.6269. 54. Lenze EJ, Mattar C, Zorumski CF et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:2292–2300. 55. Lisak RP, Nedelkoska L, Benjamins JA. Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis. J Neuroimmunol. 2020;342:577188. doi: 10.1016/j.jneuroim.2020.577188. 56. Mahdi M, Hermán L, Réthelyi JM, Bálint BL. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19. Int J Mol Sci. 2022;23(7):3812. 57. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. 58. Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016;16:22–34. 59. Miller AH. Depression and immunity: A role for T cells? Brain Behav. Immun. 2010;24:1–8. 60. NICE guideline NG188. Available at: https://www.nice.org.uk/guidance/NG188 Доступ проверен 10.07.2022. 61. Ortelli P, Ferrazzoli D, Sebastianelli L et al. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J. Neurol. Sci. 2021;420:117271. 62. Our World In Data: Coronavirus Explorer. Available at: https://ourworldindata.org/explorers/coronavirus-data-explorer Доступ проверен 08.06.2022. 63. Pashazadeh Kan F, Raoofi S et al. A systematic review of the prevalence of anxiety among the general population during the COVID-19 pandemic. J Affect Disord. 2021;293:391–8. 64. Patterson BK, Francisco EB, Yogendra R et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front Immunol. 2022;12:746021. doi: 10.3389/fimmu.2021.746021. 65. Reis G, dos Santos Moreira-Silva EA, Silva DM et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. Lancet Glob. Health. 2022;10:e42–e51. 66. Riesner HJ, Zeitler C, Schreiber H, Wild A. Additional treatment in chronic pain syndrome due to hip and knee arthritis with the selective serotonin reuptake inhibitor fluvoxamine (Fevarin). Z Orthop Unfall. 2008;146(6):742-746. doi: 10.1055/s-2008-1039038. 67. Rosen DA, Seki SM, Fernández-Castañeda A et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science Transl Med. 2019. doi: 10.1126/scitranslmed.aau5266. 68. Ruiz P. Comprehensive textbook of psychiatry. Cambridge Press, 2017. 69. Ruiz-Cantero MC, González-Cano R, Tejada MA et al. Sigma-1 receptor: A drug target for the modulation of neuroimmune and neuroglial interactions during chronic pain. Pharmacol Res. 2021;163:105339. doi: 10.1016 /j.phrs.2020.105339. 70. Ruscher K, Wieloch T. The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration. J Pharmacol Sci. 2015;127(1):30-35. doi: 10.1016 /j.jphs.2014.11.011. 71. Sałaciak K, Pytka K. Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders. Neurosci Biobehav Rev. 2022;132:1114-1136. doi: 10.1016/j.neubiorev.2021.10.037. 72. Sanchez EL, Lagunoff M. Viral activation of cellular metabolism. Virology. 2015;479-480:609-618. doi: 10.1016/j.virol.2015.02.038. 73. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect. Dis. 2021;8:ofab050. 74. Sfera A, Osorio C, Rahman L et al. PTSD as an Endothelial Disease: Insights From COVID-19. Front Cell Neurosci. 2021;15:770387. doi: 10.3389/fncel. 2021.770387. 75. Shi M, Mi L, Li F et al. Fluvoxamine Confers Neuroprotection via Inhibiting Infiltration of Peripheral Leukocytes and M1 Polarization of Microglia/Macrophages in a Mouse Model of Traumatic Brain Injury. J Neurotrauma. 2022. doi: 10.1089/neu.2021.0355. 76. Skuza G. Pharmacology of sigma (σ) receptor ligands from a behavioral perspective. Curr Pharm Des. 2012;18(7):863-874. doi: 10.2174/138161212 799436458. 77. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university Press, 2013. 626 p. ISBN 978-1107686465. 78. Su TP, Hayashi T, Maurice T et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010 Dec;31(12):557-566. doi: 10.1016/j.tips.2010.08.007. 79. Su TP, Su TC, Nakamura Y, Tsai SY. The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends Pharmacol Sci. 2016;37(4):262-278. doi: 10.1016/j.tips.2016.01.003. 80. Tagashira H, Fukunaga K. Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist. Yakugaku Zasshi. 2012;132(2):167-72. doi: 10.1248/yakushi.132.167. 81. Tang SW, Leonard BE, Helmeste DM. Long COVID, neuropsychiatric disorders, psychotropics, present and future. Acta Neuropsychiatr. 2022;34(3):109-126. doi: 10.1017/neu.2022.6. 82. Torres I, Artaza O, Profeta B et al. COVID-19 vaccination: returning to WHO's health for all. Lancet Glob. Health. 2020;8(11):e1355–e1356. 83. Vasallo C, Gastaminza P. Cellular stress responses in hepatitis C virus infection: Mastering a two-edged sword. Virus Res. 2015;209:100–117. 84. Vela JM. Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy? Front Pharmacol. 2020;11:582310. doi: 10.3389/fphar.2020.582310. 85. Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. doi: 10.1016/S2213-2600(21)00031-X. 86. Wiersinga WJ, Rhodes A, Cheng AC et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793.